Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial ; volume:20 ; number:1 ; day:14 ; month:8 ; year:2020 ; pages:1-10 ; date:12.2020
BMC cancer ; 20, Heft 1 (14.8.2020), 1-10, 12.2020
- Urheber
-
Dickhoff, Chris
Senan, Suresh
Schneiders, Famke L.
Veltman, Joris
Hashemi, Sayed
Daniels, Johannes M. A.
Fransen, Marieke
Heineman, David J.
Radonic, Teodora
Ven, Peter M. van de
Bartelink, Imke H.
Meijboom, Lilian J.
Garcia-Vallejo, Juan J.
Oprea-Lager, Daniela E.
Gruijl, Tanja D. de
Bahce, Idris
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-020-07263-9
- URN
-
urn:nbn:de:101:1-2020100722321971892158
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dickhoff, Chris
- Senan, Suresh
- Schneiders, Famke L.
- Veltman, Joris
- Hashemi, Sayed
- Daniels, Johannes M. A.
- Fransen, Marieke
- Heineman, David J.
- Radonic, Teodora
- Ven, Peter M. van de
- Bartelink, Imke H.
- Meijboom, Lilian J.
- Garcia-Vallejo, Juan J.
- Oprea-Lager, Daniela E.
- Gruijl, Tanja D. de
- Bahce, Idris
- SpringerLink (Online service)
Ähnliche Objekte (12)
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
Treatment for locally resectable stage IIIC1r cervical cancer: surgery or chemoradiotherapy?
Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study
Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer
Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference
Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
ACR Appropriateness Criteria® Resectable Rectal Cancer
The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
Treatment for locally resectable stage IIIC1r cervical cancer: surgery or chemoradiotherapy?
Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study
Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer
Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference
Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
ACR Appropriateness Criteria® Resectable Rectal Cancer
The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
Treatment for locally resectable stage IIIC1r cervical cancer: surgery or chemoradiotherapy?
Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study
Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer
Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference
Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
ACR Appropriateness Criteria® Resectable Rectal Cancer
The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma